CN112741839A - Medical application of balamin A in treating deficiency hyperactivity disorder - Google Patents
Medical application of balamin A in treating deficiency hyperactivity disorder Download PDFInfo
- Publication number
- CN112741839A CN112741839A CN202110113067.6A CN202110113067A CN112741839A CN 112741839 A CN112741839 A CN 112741839A CN 202110113067 A CN202110113067 A CN 202110113067A CN 112741839 A CN112741839 A CN 112741839A
- Authority
- CN
- China
- Prior art keywords
- hyperactivity disorder
- balamin
- mouse
- treating
- medical application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- 208000013403 hyperactivity Diseases 0.000 title claims abstract description 15
- 230000007812 deficiency Effects 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- YSCJAYPKBYRXEZ-HZPINHDXSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YSCJAYPKBYRXEZ-HZPINHDXSA-N 0.000 claims description 2
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- MCOQHIWZJUDQIC-UHFFFAOYSA-N barban Chemical compound ClCC#CCOC(=O)NC1=CC=CC(Cl)=C1 MCOQHIWZJUDQIC-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 20
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000002269 spontaneous effect Effects 0.000 description 8
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 6
- AFHJQYHRLPMKHU-OSYMLPPYSA-N aloin A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-OSYMLPPYSA-N 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
- 229960002275 pentobarbital sodium Drugs 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- 230000028527 righting reflex Effects 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 241000305491 Gastrodia elata Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930193974 gastrodin Natural products 0.000 description 2
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000004617 sleep duration Effects 0.000 description 2
- 230000004620 sleep latency Effects 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of balamin A in preparing a medicament for treating deficiency and hyperactivity. The balamin A can be used for preparing the medicine for treating the deficiency hyperactivity disorder and has excellent effect.
Description
Technical Field
The invention mainly relates to the field of medicines, in particular to medical application of barbaloin A in treating deficiency hyperactivity disorder.
Background
Attention Deficit Hyperactivity Disorder (ADHD), commonly known as infantile hyperactivity disorder, has been affected by genetics, nerves, immunity, environment, society and other aspects in recent years, resulting in neurological development and psychobehavioral disorders in children with an increasingly high incidence. The symptoms of the disease are mainly hyperactivity, inattention, social disturbance and the like which are not matched with age. ADHD has a prevalence of about 6.3% in our country, with boys more likely to develop the disease than girls, and over half of the pediatric symptoms persist to adulthood.
Many studies now demonstrate that the pathogenic mechanism of ADHD may be related to the disturbance of monoamine neurotransmitters in the brain, mainly including Dopamine (DA), 5-hydroxytryptamine (5-HT), Norepinephrine (NE), etc. Wherein defects in DA anabolism are now widely recognized as the major cause of ADHD pathogenesis. While the 5-HT system is associated with cognitive impulses and emotions, which can cause impulses, attacks, hyperactivity and the like if transmitter transmission is abnormal.
Currently, most of ADHD medicines are central stimulants, antidepressant medicines and the like, the main medicines are methylphenidate and tomoxetine, but the adverse reactions are more, the recurrence rate is high after medicine withdrawal, and a lot of troubles are caused in the acquisition and management of the medicines as a tube medicine.
Over 10 years, the research on Chinese medicaments for treating the attention deficit hyperactivity disorder in China is more and more intensive, and the Chinese medicaments are important means for health preservation and treatment for thousands of years and make great contribution to the prosperity of Chinese nation. Rhizoma gastrodiae is a traditional Chinese medicine, is a perennial parasitic plant, and has been used as a medicine for more than two thousand years. Hemp was originally recorded in the Shennong herbal meridians in the warring state and the Qin-Han period. In this monograph, gastrodia elata is classified as a "top-grade" drug that has a revitalizing effect, is non-toxic, and therefore harmless for long-term use. Rhizoma Gastrodiae has wide biological and pharmacological effects, and its components have neuroprotective, antiinflammatory, and antioxidant effects, so the components of rhizoma Gastrodiae have tranquilizing, anticonvulsant, anxiolytic, and depressive effects.
Many chemical components have been isolated from gastrodia elata so far, and recent studies have confirmed that phenolic substances present in gastrodia elata are considered as main active components, and gastrodin and barcinoside having gastrodin as a structural unit are the main blood-entering active components. The method selects the barbaloin A (PA) in the barbaloin as a research object, and researches the drug effect and toxicology test of the barbaloin A on the treatment of the hyperactivity disorder. The experiment uses the spontaneous activity of mice as the main index to research the pharmacodynamic action, and uses the indexes of inflammatory factors of brain, kidney, liver and spleen, conventional white blood cells, platelets and the like to observe the toxic effect of PA on various organs of the body.
Disclosure of Invention
In order to solve the defects in the prior art, the invention provides the medical application of the barbaloin A in treating the defective hyperactivity disorder, namely the barbaloin A can be used for preparing a medicine for treating the defective hyperactivity disorder and has excellent effect.
The inventor finds that the balsamoside A can effectively reduce spontaneous movement on the premise of not influencing the levels of central serotonin and dopamine in the pharmacological activity research of the balsamoside A, plays an important role in organisms including human bodies which do not need to solve the problem of hyperpsychiasm but have excessive spontaneous movement, and is used for treating the deficiency hyperactivity disorder.
The invention also provides a pharmaceutical composition, which comprises the above-mentioned Balisenside A or its medicinal salt or its medicinal carrier.
The invention also provides a medicine which is a freeze-dried preparation, a tablet, a granule or a capsule, and the medicine is an injection, the freeze-dried preparation, the tablet, the granule or the capsule comprising the pharmaceutical composition.
Drawings
FIG. 1 is a graph showing the effect of PA on spontaneous activity in mice.
FIG. 2 is a graph showing the effect of PA on 5-HT and DA in the brain.
Fig. 3 is a graphical representation of the effect of PA on sleep latency and duration.
FIG. 4 is a graph showing the effect of PA on inflammatory factors of heart, liver, spleen and kidney.
FIG. 5 is a graph showing the effect of PA on inflammatory factors of heart, liver, spleen and kidney.
FIG. 6 is a graph showing the effect of PA on red, white, platelets and lymphocytes in a blood routine.
FIG. 7 is a graph showing the effect of PA on red, white, platelets and lymphocytes in a blood routine.
FIG. 8 is a third graph showing the effect of PA on red, white, platelets, and lymphocytes in a blood routine.
Detailed Description
The present invention will be further described with reference to specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Further, it should be understood that various changes or modifications of the present invention may be made by those skilled in the art after reading the teaching of the present invention, and such equivalents may fall within the scope of the present invention as defined in the appended claims.
Example 1: the balaneboside A can obviously reduce spontaneous movement and treat hyperactivity disorder
1. Biological material
Mice, used in the examples, were provided by the SPF laboratory animal center, university of Kunming medical, and were kept under standard laboratory conditions (temperature 25. + -. 2 ℃, 12h light/12 h dark). During the study period, the required food and water were provided and after 1 week of acclimation, the mice were randomized into two groups, one control group and one treatment group of balisonin a (pa), this example consisting of 6 mice per group. All tests were performed according to the university of Kunming animal Experimental guidelines. The protocol was approved by the institutional animal care and use committee of university of Kunming university.
2. Drugs and reagents
Balaneboside a (pa) was purchased from medea;
pentobarbital sodium was purchased from Shanxi Asia chemical Co., Ltd, and a reverse transcription Kit (Revertaid Fist Strand cDNA Synthesis Kit) was purchased from Saimer Fei Bio Inc.
All reagents used in the assay were analytically pure.
3. Treatment of
The mice in the control group and the treated group were administered with the barcinoside a and the physiological saline nasally for 8 days, respectively, or alternatively 30 minutes before the exercise activity test or the administration of the sodium pentobarbital. Pentobarbital sodium was dissolved in physiological saline and 42mg/kg (i.p.) was used as the hypnotic agent.
The group A of the Balison glycosides was administered with Balison glycoside A (drug dose 10mg/kg, drug concentration 20mg/ml, e.g. 20. mu.l for 40g nasal mice). Nasal administration step: the head of the mouse is fixed by one hand, the other hand sucks the required volume by a liquid-transferring gun and slowly drops the volume to the nostril of the mouse, the two nasal cavities drop by turns, and the nasal cavity drops the other nasal cavity after absorbing the volume, and the volume is not more than 20 mul as much as possible.
4. Spontaneous locomotor activity test
The sedative effect of balamin a (pa) was assessed by measuring spontaneous locomotor activity in mice. After the nasal cavity injection of PA and normal saline for 15-20 minutes, the mice are respectively placed in a kinetic energy tester.
The exercise capacity and the number of times of standing can be calculated using a YLS-1A exercise capacity tester (Jinan Yiyan science and technology development Co.) consisting of five connected transparent cells and five infrared sensors. A small amount of padding is put into each detection chamber, and the mice are put into the chambers to adapt for 5-10 minutes and then start to perform activity counting. After the start of the recording, the activity count was increased for each mouse movement in the chamber, and the number of mouse activities within 2 hours after nasal administration was recorded. After each test, the tester housing is preferably thoroughly cleaned with 70% ethanol. The test results are shown in FIG. 1.
5. Pentobarbital sodium induced sleep test
Pentobarbital sodium injection experiments were performed between 9:00 am and 5:00 pm, and the sleep time of each mouse was observed after pentobarbital sodium injection. When the mice lost righting reflex disappeared, they were considered to be in a sleeping state.
The righting reflex is defined as the inability of a mouse to self-right when placed in a dorsal decubitus position for at least 30 seconds. The reflex from administration of sodium pentobarbital to loss of the righting reflex is recorded as sleep latency. And the time from disappearance of righting reflex to recovery was recorded as the sleep duration. The test results are shown in FIG. 3.
RT-PCR experiment
The mouse is killed by cervical dislocation, blood is taken from eye socket of the mouse, eyeball is taken by tweezers, and the blood flows into EP tube from the eye socket. Then, the abdominal organs and the brain and scalp of the mouse are cut off by surgical scissors, about 0.1g of the brain, the heart, the spleen, the kidney and the liver of the mouse are picked up respectively, and the mouse is immediately put into a refrigerator at the temperature of 80 ℃ below zero for storage.
7. Dopamine (DA) and serotonin (5-HT) detection
Mice were sacrificed by cervical dislocation, whole brain homogenate of about 0.1g was taken, 1g tissue was added with 9ml of PBS, and specimens were homogenized thoroughly by hand or by a homogenizer. The supernatant was collected by centrifugation for about 20 minutes (3000 rpm 2000). The DA and 5-HT neurotransmitter levels in the brains of the mice to be tested were used by the elisa method (elisa kit, commercially available from Shanghai enzyme-linked biosciences). The test results are shown in FIG. 2.
8. Routine blood test
The mouse is placed in a 4-degree refrigerator for storage after blood is taken, and a blood sample feeding conventional detector detects various conventional indexes of the mouse blood. The test results are shown in FIGS. 6 to 8.
9. Detecting expression of related genes
Taking the whole brain, spleen, liver and kidney of a mouse, cracking by using Trizol 1mL, extracting total RNA by using a reagent, and then performing reverse transcription to obtain cDNA for RT-PCR experiment detection of the expression of related genes at the RNA level. The test results are shown in FIGS. 4-5.
The results of mouse ethology prove that pa obviously reduces spontaneous movement, the levels of whole brain serotonin and dopamine are not changed, and inflammatory factors of heart, liver, spleen and kidney are not changed, which indicates that the internal organs are not damaged. Therefore, the balsamoside A can reduce spontaneous movement without affecting the level of serotonin and dopamine in the center, and can be used in organisms including human bodies which do not need to solve the problem of hyperpsychosis but have excessive spontaneous movement, and can be used for treating the deficiency hyperactivity disorder.
The above description is only a preferred embodiment of the application and is illustrative of the principles of the technology employed. It will be appreciated by a person skilled in the art that the scope of the invention as referred to in the present application is not limited to the embodiments with a specific combination of the above-mentioned features, but also covers other embodiments with any combination of the above-mentioned features or their equivalents without departing from the inventive concept. For example, the features described above have similar functions to (but are not limited to) those disclosed in this application.
Claims (3)
1. The use of the barban glycoside A in preparing a medicament for treating the deficiency hyperactivity disorder.
2. A pharmaceutical composition comprising the barbaloin a or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable carrier thereof of claim 1.
3. A pharmaceutical which is a lyophilizate, a tablet, a granule or a capsule, characterized in that said pharmaceutical is an injection, a lyophilizate, a tablet, a granule or a capsule comprising the pharmaceutical composition of claim 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110113067.6A CN112741839A (en) | 2021-01-27 | 2021-01-27 | Medical application of balamin A in treating deficiency hyperactivity disorder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110113067.6A CN112741839A (en) | 2021-01-27 | 2021-01-27 | Medical application of balamin A in treating deficiency hyperactivity disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112741839A true CN112741839A (en) | 2021-05-04 |
Family
ID=75653238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110113067.6A Pending CN112741839A (en) | 2021-01-27 | 2021-01-27 | Medical application of balamin A in treating deficiency hyperactivity disorder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112741839A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115120603A (en) * | 2022-08-17 | 2022-09-30 | 北京大学口腔医学院 | Application of Parishin A in preparation of macrophage polarization function regulator |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140676A1 (en) * | 2010-05-12 | 2011-11-17 | 北京科莱博医药开发有限责任公司 | Rhizoma gastrodiae plant extract used to prevent and treat alzheimer disease and vascular dementia and mixed type diseases thereof and preparative method thereof |
| CN103626812A (en) * | 2013-12-10 | 2014-03-12 | 江西本草天工科技有限责任公司 | Novel parishin compound in gastrodia elata and application of compound |
| CN108498802A (en) * | 2018-05-10 | 2018-09-07 | 西安培华学院 | pharmaceutical composition for treating non-small cell lung cancer and its preparation |
-
2021
- 2021-01-27 CN CN202110113067.6A patent/CN112741839A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140676A1 (en) * | 2010-05-12 | 2011-11-17 | 北京科莱博医药开发有限责任公司 | Rhizoma gastrodiae plant extract used to prevent and treat alzheimer disease and vascular dementia and mixed type diseases thereof and preparative method thereof |
| CN103626812A (en) * | 2013-12-10 | 2014-03-12 | 江西本草天工科技有限责任公司 | Novel parishin compound in gastrodia elata and application of compound |
| CN108498802A (en) * | 2018-05-10 | 2018-09-07 | 西安培华学院 | pharmaceutical composition for treating non-small cell lung cancer and its preparation |
Non-Patent Citations (2)
| Title |
|---|
| TANG, CL ET AL: "Analysis of the metabolic profile of parishin by ultra-performance liquid chromatography/quadrupole-time of flight mass spectrometry", 《BIOMEDICAL CHROMATOGRAPHY》 * |
| 邹宁 等: "天麻素对小鼠的镇静催眠作用", 《时珍国医国药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115120603A (en) * | 2022-08-17 | 2022-09-30 | 北京大学口腔医学院 | Application of Parishin A in preparation of macrophage polarization function regulator |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102548571B (en) | Compositions and methods for prevention and treatment of brain diseases and conditions | |
| CN108135865A (en) | Use the method for fenfluramine treatment Lennox-Gastaut syndromes | |
| CN100438876C (en) | Use of 20(S)-protopanoxadiol in preparation of antidepressant medicine | |
| US20110059124A1 (en) | The quality control method and application of a kind of ganoderma lucidum spore oil fat emulsion | |
| CN104784270B (en) | A kind of swelling and pain relieving external preparation and preparation method thereof | |
| Ansari et al. | Nigella sativa: A non-conventional herbal option for the management of seasonal allergic rhinitis | |
| Fernandes et al. | The importance of diagnosing and the clinical potential of treating obstructive sleep apnea to delay mild cognitive impairment and Alzheimer’s disease: a special focus on cognitive performance | |
| CN112741839A (en) | Medical application of balamin A in treating deficiency hyperactivity disorder | |
| CN102727486B (en) | Application of Inula lineariifolia lactone A in preparation of medicine for treating myocarditis | |
| Wang et al. | Clinical effect of sequential therapy with azithromycin in children mycoplasma pneumoniae pneumonia. | |
| Tillisch et al. | Diagnosis and treatment of irritable bowel syndrome: state of the art | |
| US9782366B2 (en) | Drug for killing acid-fast (red) bacillus | |
| CN103108639A (en) | Composition of active ingredient of traditional chinese medicine and use thereof | |
| CN108578667A (en) | A kind of drug that treating methamphetamine abstinence syndrome and its application | |
| CN109381473A (en) | Scutelloside is in the application for preparing gestational diabetes Fetal neurotubules malformation drug | |
| CN102335338B (en) | Chinese medicinal compound preparation for improving parkinson disease brain neurotransmitter metabolism | |
| CN1739682A (en) | Nudiflorous beautyberry soft capsule for body cavity and its prepn | |
| JP7090731B2 (en) | New pharmaceutical uses of persimmon leaf extract and its preparations | |
| CN101879151A (en) | Application of emodin in preparing medicaments for treating P2X3 mediated neuropathic pains/nerve system diseases | |
| CN101274031A (en) | Medicament composition for curing irritable bowel syndrome | |
| Yoon et al. | Effects of cynanchum wilfordii hemsley extract on the sleep-wake architectures in rats | |
| CN113181163B (en) | Application of oroxylin A in preparation of medicine for treating pulmonary fibrosis | |
| CN106924448A (en) | Treat pharmaceutical composition of anemopyretic cold and preparation method thereof | |
| Zhu et al. | Relieving Effect of Naringenin on Constipation in Mice and Its Effect on Intestinal Flora in Mice. | |
| CN101612160B (en) | Application of 20(S)-ginsenoside Rh2 compound in preparing antidepressant medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |